[Clinical trial of cefuzonam in biliary infection].
For the evaluation of efficacy of cefuzonam (CZON) on biliary infection, the drug was administered to 12 cases of hepatic, biliary, and pancreatic diseases with postoperative/post-percutaneous transhepatic biliary drainage (PTBD) infections. The results were summarized as follows: The bacterial eradication rate was 33.3% (9/27 strains). Nine strains of bacteria appeared during the administration of CZON. MIC's of CZON against 14 strains including 4 of K. oxytoca out of 53 strains tested were below 1.56 micrograms/ml, whereas MIC's against 39 strains including 22 Pseudomonas spp. were higher than 12.5 micrograms/ml. Leukocyte counts in bile decreased in 6 cases, increased in 2 cases, and not detected in 1 case, showing no correlation with changes in bacteriology or clinical symptoms. Improvements of clinical symptoms such as reduced pain and decreased fever were noted in all cases. No case of adverse reaction was observed. The results indicated that CZON would be an antibiotic with a high efficacy and safety on biliary infections.
D000328:Adult; D000368:Aged; D001424:Bacterial Infections / Q000188:drug therapy* / Q000382:microbiology; D001646:Bile / Q000382:microbiology; D001660:Biliary Tract Diseases / Q000188:drug therapy* / Q000382:microbiology; D015296:Ceftizoxime / Q000031:analogs & derivatives*; D002511:Cephalosporins / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged
D002511:Cephalosporins; C049934:cefuzonam; D015296:Ceftizoxime